Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Struct Mol Biol. Author manuscript; available in PMC 2009 September 14.
Published in final edited form as:
PMCID: PMC2743565

Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ


The nuclear receptors REV-ERBα (encoded by NR1D1) and REV-ERBβ (NR1D2) have remained orphans owing to the lack of identified physiological ligands. Here we show that heme is a physiological ligand of both receptors. Heme associates with the ligand-binding domains of the REV-ERB receptors with a 1:1 stoichiometry and enhances the thermal stability of the proteins. Results from experiments of heme depletion in mammalian cells indicate that heme binding to REV-ERB causes the recruitment of the co-repressor NCoR, leading to repression of target genes including BMAL1 (official symbol ARNTL), an essential component of the circadian oscillator. Heme extends the known types of ligands used by the human nuclear receptor family beyond the endocrine hormones and dietary lipids described so far. Our results further indicate that heme regulation of REV-ERBs may link the control of metabolism and the mammalian clock.

REV-ERBα was originally identified as an orphan member of the nuclear hormone receptor (NHR) family on the basis of its canonical domain structure and sequence conservation1,2. REV-ERBβ was subsequently identified by its homology to other NHRs and its pattern of expression, which overlaps greatly with that of REV-ERBα. Both receptors have particularly high expression in the liver, adipose tissue, skeletal muscle and brain38, where they are transcribed in a circadian manner911. The REV-ERBs are unique in the NHR superfamily in that they lack the carboxy-terminal tail (helix 12) of the ligand-binding domain (LBD), which is required for coactivator recognition12 (Supplementary Fig. 1a online). Both receptors act as constitutive repressors of transcription and bind DNA response elements termed ‘ROREs’1315. Although considerably more is known about the function of REV-ERBα than that of REV-ERBβ, the similarities in their expression patterns and DNA-binding and transcriptional activities indicate that they are likely to overlap substantially in function. Nevertheless, more complete understanding of their functional properties has been hindered by the lack of known physiological ligands.

REV-ERBα is a principal regulator of the cyclic expression of BMAL1 (refs. 1618), a key component of the mammalian circadian clock. Circadian rhythms play an essential part in aspects of physiology and behavior, including the sleep-wake cycle, body temperature, blood pressure and renal function. The circadian rhythms are generated by feedback loops in gene expression in which heterodimers of BMAL1 and CLOCK activate expression of the cryptochrome (Cry) and period (Per) genes (the negative limb)19,20. When CRY and PER reach a critical level of expression, they block the stimulatory effect of the CLOCK or NPAS2–BMAL1 complex on their own genes, thereby completing the loop20,21. The BMAL1 promoter contains two ROREs, and BMAL1 transcription is directly repressed by REV-ERBα16,22. Mice deficient in NR1D1, the gene encoding REV-ERBα, show loss of the diurnal pattern of expression of BMAL1 and alterations in the period and phase of their circadian behavior patterns17.

Clues to a possible physiological ligand for the REV-ERB proteins has come from a study on E75, a member of the NHR family in Drosophila that has been shown to contain a heme prosthetic group23. The oxidation state of iron-heme in E75 determines whether this NHR can interact with its heterodimer partner, DHR3, and this dimer interaction is further regulated by binding of either nitric oxide or carbon monoxide to heme23. The heme in E75 is highly resistant to dissociation, and its forcible removal produces an unstable protein23,24. Thus, heme could be involved in the regulation of E75 activity by influencing its stability, or by functioning as a sensor of redox and/or diatomic gases23. Alignment of the LBDs of E75 and the REV-ERB receptors shows good conservation overall (Supplementary Fig. 1b). Because heme concentrations change in a circadian manner and can entrain the mammalian clock25,26 and because heme is used as a cofactor by proteins that control metabolic functions and the circadian clock including NPAS2 (ref. 27), we have examined whether the human REV-ERB nuclear receptors use heme as their ligand.


REV-ERB proteins are associated with heme

We purified recombinant histidine-tagged human REV-ERBα and REV-ERBβ LBD proteins after expression in Escherichia coli. We also prepared Flag-tagged full-length REV-ERBα and REV-ERBβ by transient transfection of human embryonic kidney HEK293 cells. Both cell systems are known to produce heme that associates with heme-binding proteins28,29, and recombinant E75 protein expressed in E. coli has been shown to associate tightly with heme23.

Both full-length receptors and LBDs were extensively purified, and the samples were notably red or pink in color (Supplementary Fig. 2 online). Matrix-assisted laser desorption-ionization (MALDI) mass spectra of these samples showed a heme peak, corresponding to iron-protoporphyrin IX, with the expected mass of 616 ± 2 Da (mean ± s.d.; Fig. 1a and Supplementary Fig. 3 online). The distinct features of heme bound to the proteins were observed by ultraviolet-visible spectroscopy: namely α and β peaks in the 500–600 nm range and γ (Soret) peaks in the 390–450 nm range (Fig. 1b and Supplementary Fig. 4 online). In addition, the associated heme was in the oxidized state because the Soret peak was shifted on addition of the reducing agent dithionite (Fig. 1b).

Figure 1
Association of heme with the LBDs from REV-ERBα and REVERBβ. (a) MALDI mass spectra showing iron protoporphyrin IX in purified REV-ERBα and REV-ERBβ LBDs prepared from E. coli. Signals at 616 ± 2 Da correspond to ...

Heme binding thermodynamics

To characterize the thermodynamics of heme binding to REV-ERB proteins, we used isothermal titration calorimetry (ITC) after removing heme from the purified LBDs. In contrast to Drosophila melanogaster E75, heme can be removed from the REV-ERB LBDs by extensive washing of Ni-NTA–immobilized proteins or through dialysis (Supplementary Fig. 5 online).

Heme-depleted receptors were appropriately folded and fully competent to bind exogenously added heme, as shown by the ITC measurements; both REV-ERB LBDs bound to heme with a dissociation constant (Kd) of 2–3 μM (Fig. 2a,b). The enthalpy of heme binding was approximately −5 kcal mol−1, and the stoichiometry of heme to receptor binding was roughly 1:1. Thus, heme binding to the REV-ERB LBDs is fully reversible. Although the concentration of heme in different tissues is not known, it has been suggested that they vary in a circadian manner29, indicating that REV-ERBs might function as heme sensors.

Figure 2
Thermodynamics of heme association with the REV-ERB LBDs measured by ITC and circular dichroism spectroscopy. (a,b) ITC data corresponding to the REV-ERBα (a) and REV-ERBβ (b) LBDs binding hemin. (c,d) Far-ultraviolet circular dichroism ...

Heme binding increases REV-ERB LBD thermal stability

Nuclear receptor ligands are generally lipophilic and increase protein thermal stability by binding a hydrophobic central cavity in the LBDs. We examined the effect of heme binding on thermal stability of the LBD by using circular dichroism spectroscopy. Heme binding increased the melting temperature (Tm) of each LBD by 4–5 °C (Fig. 2c,d), consistent with ligand effects on other nuclear receptor LBDs, for which it typically increases the Tm by 1–6 °C (refs. 30,31). These results suggested that a change in protein conformation occurs on heme binding to REV-ERB LBDs, and this idea was supported by peptide interaction ‘conformation sensing’ assays (Supplementary Fig. 6 and Supplementary Methods online).

Taken together, these data are consistent with the hypothesis that REV-ERBs act as physiological sensors of heme concentrations in cells and that heme binding may act as the molecular switch that regulates receptor conformation.

A REV-ERBα LBD mutant deficient in heme binding

Most heme binding proteins use histidine side chains to coordinate the heme molecule. In E75, mutation of particular histidine or cysteine residue eliminates heme binding23,24, and some of these residues are conserved in REV-ERBα and REV-ERBβ (Supplementary Fig. 1). We individually mutated residues Cys389 (conserved in REV-ERBα and REV-ERBβ), and Cys418 and His602 (conserved in E75 and both REV-ERBs) in the LBD of REV-ERBα. All three mutant LBDs were stable when expressed in E. coli and were purified for ITC analysis of their ability to bind heme.

C389A and C418A showed affinities for heme similar to that of the wild-type LBD (data not shown). By contrast, REV-ERBα LBD H602F showed substantially diminished affinity for binding heme (Kd: wild type, 3.5 ± 0.2 μM; H602F, > 120 μM; Fig. 3). In addition, ultraviolet-visible spectrum analysis indicated that the H602F mutant was not associated with heme (Fig. 3), implying that H602 is essential for heme binding to the REV-ERBα LBD.

Figure 3
Role of heme in regulation of REV-ERBα LBD activity. (a) Ultraviolet-visible spectrum of wild-type REV-ERBα (blue) and H602F REV-ERBα (red) LDBs. The absorbance peaks at 280 nm indicate that similar amounts of wild-type and H602F ...

Heme is required for the repressor activity of REV-ERBα LBD

To examine the role of heme in REV-ERBα function in cells, we assessed the transcriptional repressor activity of REV-ERBα LBD and the H602F mutant, fused to the DNA-binding domain (DBD) of Gal4 in both HuH7 hepatoma cells and HEK293 cells. Use of the Gal4 DBD chimeric receptors facilitated direct assessment of the transcriptional repressor activity of the LBDs in isolation.

Both fusions were expressed in similar amounts, as determined by immunoblotting (Supplementary Fig. 7a online). There was, however, a complete loss in transcriptional repression activity of the H602F LBD, as compared with the wild-type LBD (Fig. 3), suggesting that heme binding is required for repression.

Heme regulates the expression of REV-ERBα target genes

The lack of ability of the Gal4 DBD REV-ERBα LBD H602F mutant to repress transcription suggested that heme might be required for the repressive effect of REV-ERBα on its target genes. To test this idea, we modulated intracellular heme in human HepG2 hepatoblastoma cells and examined the effects on the REV-ERBα target genes BMAL1 and ELOVL3. We inhibited heme biosynthesis in cells with succinylacetone, a highly specific inhibitor of aminolevulinic acid dehydratase that has been used to decrease intracellular heme in several cell lines and in vivo3237.

Although intracellular heme is usually tightly regulated, we effectively reduced intracellular concentrations by about 40% using succinylacetone (Fig. 4a). This reduction was accompanied by a 2.6-fold increase in the expression of ALAS1 (Fig. 4b), the gene encoding aminolevulinic acid synthase. Because ALAS1 expression is known to be under negative transcriptional feedback control by heme34, the observed upregulation of ALAS1 on succinylacetone treatment indicates that the decrease in heme is physiologically significant. By contrast, addition of hemin to the cells resulted in a significant (P < 0.05) 33% increase in intracellular heme (Fig. 4a), accompanied by a 40% decrease in ALAS1 expression, again consistent with the physiological response to an excess of intracellular heme. As an alternative to succinylacetone method, the effect of inhibition of ALAS1 expression by short interfering RNA (siRNA) was also examined. We found, however, that there was no correlation between inhibition of ALAS1 and a decrease in intracellular heme (potentially owing to compensatory effects of heme oxygenase) and, as a result, we did not pursue further the siRNA approach for modulation of heme.

Figure 4
Effect of modulation of intracellular heme on expression of REV-ERB target genes in HepG2 cells. (a) Treatment of HepG2 cells with succinylacetone (−heme) results in depletion of intracellular heme, whereas addition of hemin results in an increase ...

In heme-depleted cells, we noted a significant (P < 0.05) increase in expression of BMAL1 (3-fold) and ELOVL3 (5.5-fold; Fig. 4c,d). The increase in expression of REV-ERB target genes that followed heme depletion was consistent with our data on the chimeric H602F LBD, suggesting that an ability to bind heme is required for the repressor activity of REV-ERB LBD. We expected that increasing intracellular heme would result in a decrease in expression of REVERB target genes, owing to an increase in repressive activity. Indeed, raising intracellular heme caused significant (P < 0.05) decreases in BMAL1 and ELOVL3 expression (Fig. 4c,d). These data are consistent with our hypothesis that heme selectively regulates the transcription of REV-ERB target genes.

Heme regulates NCoR recruitment to REV-ERBα

REV-ERBs repress the transcription of their target genes through recruitment of the co-repressor NCoR38,39. The inability of the H602F REV-ERBα LBD mutant to repress transcription, in addition to the observation that intracellular heme regulates the expression of REV-ERBα target genes, suggests that heme may regulate the ability of REV-ERBα to interact with NCoR. Consistent with this hypothesis, depleting intracellular heme resulted in a decreased interaction of REV-ERBα with NCoR, as determined by co-immunoprecipitation. (Fig. 5a). Addition of 30 μM hemin to the heme-depleted cells resulted in partial recovery of the interaction between REV-ERBα and NCoR (Fig. 5b). Depletion of heme also resulted in a large decrease in NCoR occupancy of the RORE in the BMAL1 promoter, as determined by chromatin immunoprecipitation (ChIP) and quantitative PCR (Fig. 5b). Similar to the co-immunoprecipitation results, addition of hemin to the heme-depleted cells resulted in partial recovery of NCoR occupancy of the BMAL1 promoter (Fig. 5b). It should be noted that the co-immunoprecipitation and ChIP studies were performed in HepG2 cells expressing endogenous amounts of REV-ERBα and NCoR. These data indicate that heme can regulate the interaction of REV-ERBα with NCoR and are also consistent with the hypothesis that heme regulates REV-ERB–mediated recruitment of NCoR to the BMAL1 promoter.

Figure 5
Effect of intracellular heme on NCoR interaction with REV-ERBα and recruitment to promoters. (a) The interaction of REV-ERBα with NCoR in HepG2 cells was determined by coimmunoprecipitation. Heme was depleted by succinylacetone treatment ...

REV-ERB LBDs appear not to be redox or gas sensors

In other types of heme–protein complexes, the heme prosthetic group confers the ability to respond either to alterations in redox state or to diatomic gases. We found that reduction of the heme iron through the addition of 10 μM dithionite did not substantially change the binding activity of the CoRNR box peptide, suggesting that the redox state of heme does not alter LBD conformation (Supplementary Fig. 8a,b online). Addition of pharmacological nitric oxide donors did not affect the transcriptional activity of the REV-ERB LBD (Supplementary Fig. 8a,b). Thus, in contrast to E75, REV-ERBs seem to be insensitive to the redox state and diatomic gasses.


We have shown that heme meets the requirements of a physiological ligand for the human orphan nuclear receptors REV-ERBα and REVERBβ. Heme binding took place in a 1:1 stoichiometry with the REVERB LBDs, as determined by ITC (Fig. 2a,b), and, consistent with the role of heme as a REV-ERB ligand, the receptor LBDs underwent changes in thermal stability and conformation on heme addition (Fig. 2c,d and Supplementary Fig. 6). Modulation of intracellular heme resulted in a change in the expression of REV-ERB target genes (Fig. 4) and in alteration of the interaction of REV-ERBα with NCoR (Fig. 5a). The effects of heme were specific to the REV-ERB LBDs because we observed no effect on other nuclear receptors such as LXR (Supplementary Fig. 6). These results are consistent with the idea that the REV-ERBs function as physiological sensors of intracellular heme. The identification of a member of the nuclear receptor superfamily as a heme receptor indicates that the diversity of endogenous ligands for this superfamily is more extensive than the steroids, retinoids, thyroid hormone and lipids identified so far. The affinity of heme for the REV-ERB LBDs (Kd ≈ 3 μM) suggests that these receptors belong in the category of physiological nuclear receptor ‘metabolite’ sensors, such as FXR (bile acids), LXR (oxysterols) and PPARs (fatty acids), for which Kd values of 1–10 μM have been observed40.

Although the Drosophila E75 protein also associates with heme, there are many important differences between E75 and the two human REV-ERB proteins characterized here. In biochemical assays, the REV-ERB LBDs show reversible binding with heme and stability in both the ligand-bound and apoprotein state (Supplementary Fig. 6). By contrast, binding of heme to E75 seems to be constitutive and is required for protein stability23. We found that, in the REV-ERB LBDs, a change in the oxidation state of the iron does seem to alter receptor conformation (Supplementary Fig. 9a,b online). In addition, the transcriptional activity of the REV-ERB does not seem to be responsive to diatomic gases. Thus, it seems that REV-ERBs function as sensors of heme, rather than using heme to sense redox conditions or gases.

Variations in intracellular heme, which occur in a circadian manner in mammals25, may allow REV-ERB proteins to modulate repression of their target genes and to shape appropriately the amplitude of the circadian rhythm. REV-ERBα regulates the expression of several genes involved in circadian pathways and in lipid metabolism and adipogenesis16,4146. Our findings indicate that the REV-ERBs sense and respond to dynamic changes in intracellular free heme and may use heme to integrate the circadian clock and metabolic programs. Importantly, the REV-ERB target gene BMAL1, an essential component of the circadian oscillator, is also essential for adipogenesis47,48. Such links between circadian rhythms and metabolic patterns have been recognized for some time19,48. More direct evidence has come from mice carrying mutations in BMAL1 or Clock. These mice show abnormalities similar to metabolic syndrome including obesity, dyslipidemia and impaired glucose metabolism49,50. Our finding that the REV-ERBs are in fact ligand-regulated receptors suggests that synthetic modulators of the REV-ERB proteins may be developed in the future with the goal of treating human diseases related to coordination of the cellular clock, control of glucose and energy metabolism.

Synthesis of heme, the ligand for the REV-ERBs, is linked to the nutritional status of mammals through the regulation of ALAS1 by the nuclear receptor coactivator PGC-1α (ref. 51). This coactivator is induced by fasting and mediates the transition from glucose to fatty acid use as an energy source and has been shown to integrate the mammalian clock and energy metabolism52. We predict that alterations in PGC-1α–induced expression of ALAS1, along with the rate of heme synthesis, may provide a direct pathway for modulating REV-ERB–mediated regulation of the circadian rhythm and energy metabolism, thereby serving as an additional link between these two crucial and intricately regulated biological processes. Finally, REV-ERBα is involved in the induction of adipogenesis, and we predict that heme has a crucial role in this process. Indeed, heme has been shown to be essential in the induction of adipocyte differentiation53, and our results suggest that this role of heme may be mediated by REV-ERB, which also plays an important part in adipogenesis.


Expression and purification of REV-ERBα and REV-ERBβ

For LBDs, residues 281–614 of REV-ERBα (NM_021724) and 247–579 of REV-ERBβ (NM_005126) were expressed as 6×His-tagged proteins from a pET46 Ek/Lic vector in Rosetta (DE3)-pLysS E. coli cells (Novagen). We added 150 μM 5-amino levulinic acid to the cultures to enhance expression of the proteins. The cells were induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) at 16 °C overnight, collected and lysed in 20 mM Tris (pH 8.0), 500 mM NaCl, 20 mM imidazole and 10% glycerol. The proteins were purified with His-Bind Resin (Novagen) and eluted with 250 mM imidazole. The purified LBDs were dialyzed against 20 mM Tris, 200 mM NaCl and 5% glycerol for subsequent experiments. LBD concentrations were estimated by using the calculated molar extinction coefficient (ε280) of 0.619 = 1 mg/ml (for REV-ERBα) and 0.393 = 1 mg/ml (for REV-ERBβ). The bound heme concentration was estimated by using the extinction coefficient for the heme Soret peak (ε415) of 101.85 = 1 mM.

For mammalian expression of full-length receptors, pCMV7.1_3X plasmids containing Flag-tagged REV-ERBα and REV-ERBβ were transiently transfected into suspension-adapted 293-EBNA cells (CRL-10852, ATCC; 10 l at 106 cells per ml). After 24 h, bovine hemin (H 5533, Sigma-Aldrich) was added at 1 mg/l. After 48 h, cells were collected, frozen at −80 °C, and lysed with Cell Lytic M buffer (Sigma-Aldrich). The proteins were purified by using a Flag M2 affinity (Sigma) column and eluted with 3×Flag peptide (Sigma-Aldrich). The presence of REV-ERBα and REV-ERBβ in the eluted fractions was assessed by immunoblotting using a Flag M2 monoclonal antibody (Sigma-Aldrich). The presence of heme was determined by the Soret band (415 nm).

Ultraviolet-visible spectroscopy

Soret and α,β absorption spectra were measured on a Cary 50 Bio ultraviolet-visible spectrophotometer at room temperature (22 °C). To reduce the heme group, 10 mM sodium hydrosulfite (dithionite) was added to the protein samples. Spectra of reduced complexes were recorded 5 (for REV–ERBα) or 50 (for REV–ERBβ) min after the addition of 10 mM dithionite.

Mass spectrometry

The REV-ERBα and REV-ERBβ LBDs and the Flag-tagged full-length proteins were first dialyzed against water to remove salt. Protein concentrations of 0.5–1 mg/ml were used for MALDI mass spectrometry analyses. The samples were analyzed at the Biomolecular Facility of the University of Virginia as described in the Supplementary Methods.


We carried out ITC experiments at 20 °C on a MicroCal VP-ITC instrument. For heme binding studies, LBDs were dialyzed extensively against 20 mM Tris (pH 8.0), 200 mM NaCl and 5% glycerol, and then concentrated in the same buffer to 0.050 mM (REV-ERBα) or 0.045 mM (REV-ERBβ). The concentration of hemin solution in the ITC binding studies was 0.466 mM (for REV-ERBα) or 0.561 mM (for REV-ERBβ).

Circular dichroism

Purified LBDs were dialyzed against 10 mM NaH2PO4 (pH 7.5) and 50 mM NaCl. Measurements were carried out on an AVIV circular dichroism instrument. For temperature melting experiments, a gradient of 20–70 °C was used with 2 °C jumps and a 2-min equilibration time. The change in circular dichroism signal was measured at 223 nm and 224 nm for REV-ERBα and REV-ERBβ, respectively. Protein concentrations were 0.4 mg/ml. Similar measurements were repeated after the addition of 50 μM hemin to the protein samples54.

Measurement of cellular heme content

Heme in HepG2 cell lysates was measured by using a modified QuantiChrom Heme Assay (BioAssay Systems). The amount of heme in each sample is expressed as μM heme per mg of total protein.

Manipulations of heme biosynthesis

Succinylacetone (Sigma) was added to confluent HepG2 cultures at a final concentration of 0.5 mM (ref. 32) for 24 h before cell collection. We added 30 μM hemin (Sigma) to confluent cultures for 24 h before cell collection as described55. Hemin was added either in the absence of succinylacetone (Fig. 4) or in the presence of succinylacetone (simultaneous treatment; Fig. 5).

Quantitative RT-PCR

Quantitative RT-PCR was performed as described56. The BMAL1 (NM_001178) primers were (5′-GTACCAACATGCAACGCAATG-3′) and (5′-TGTGTATGGATTGGTGGCACC-3′). Cyclophilin B (M60857) was used as a standard with the following primers: (5′-GGAGATGGCACAGGAGGAAA -3′) and (5′-CGTAGTGCTTCAGTTTGAAGTTCTCA-3′). ELOVL3 primers were obtained from Superarray.

ChIP assay

ChIP assays were performed as described38,57. Chromatin-immunoprecipitated DNA was quantified by quantitative PCR with the following primers specific to the human BMAL1 promoter: BMAL1_prom-for (5′-ATTGGTGGCAGGAAAGTAGC-3′) and BMAL1_prom-rev (5′-GTTGTGTGGCGGCTAGAGAG-3′).

Co-immunoprecipitation assay

HepG2 cells were treated with succinylacetone (2 mM) or both succinylacetone (2 mM) and hemin (30 μM) for 24 h before immunoprecipitation. Cells were lysed in Triton lysis buffer (20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 1.5 mM MgCl2, 1 mM dithiothreitol, 1 mM phenylmethylsulphonyl fluoride, 10 mg/ml of aprotinin and 10 mg/ml of leupeptin). Protein concentrations were measured with BCA Protein Assay Reagent (Pierce) and ~0.5 mg of protein lysate was used for each immunoprecipitation. The antibodies used for immuno-precipitation and immunoblotting were anti–REV-ERBα (Cell Signaling Technologies) and anti–NCoR C-20 (Santa Cruz Biotechnology).

Co-transfection and reporter assays

HuH7 and HEK293 cells were seeded in 96-well plates at 25,000 cells per well as described58 with the modifications outlined in the Supplementary Methods.

Supplementary Material



This work was supported by a grant from the National Institutes of Health (GM055217) to F.R. and an unrestricted research grant from Eli Lilly and Company to T.P.B.


Note: Supplementary information is available on the Nature Structural & Molecular Biology website.


S.R. produced the wild-type and mutant constructs and, together with P.H., purified the proteins and carried out mass spectrometry and ultraviolet-visible spectroscopy. P.H. and S.K. designed and performed the ITC and circular dichroism studies. K.R.S. performed co-transfection and luminex assays. P.M.R. performed the co-immunoprecipitation and ChIP assays. D.B.M. expressed REVERBs in HEK293 cells. A.K.N and L.L.B. created REV-ERB mutants and performed co-transfection assays. T.P.B. and F.R. conceived and designed the studies and wrote the manuscript.

Reprints and permissions information is available online at


1. Miyajima N, et al. Two erbA homologs encoding proteins with different T3 binding capacities are transcribed from opposite DNA strands of the same genetic locus. Cell. 1989;57:31–39. [PubMed]
2. Miyajima N, et al. Identification of two novel members of erbA superfamily by molecular cloning: the gene products of the two are highly related to each other. Nucleic Acids Res. 1988;16:11057–11074. [PMC free article] [PubMed]
3. Lazar MA, Hodin RA, Darling DS, Chin WW. A novel member of the thyroid/steroid hormone receptor family is encoded by the opposite strand of the rat c-erbAα transcriptional unit. Mol Cell Biol. 1989;9:1128–1136. [PMC free article] [PubMed]
4. Bonnelye E, et al. Rev-erbβ, a new member of the nuclear receptor superfamily, is expressed in the nervous system during chicken development. Cell Growth Differ. 1994;5:1357–1365. [PubMed]
5. Dumas B, et al. A new orphan member of the nuclear hormone receptor superfamily closely related to Rev-Erb. Mol Endocrinol. 1994;8:996–1005. [PubMed]
6. Enmark E, Kainu T, Pelto-Huikko M, Gustafsson JA. Identification of a novel member of the nuclear receptor superfamily which is closely related to Rev-ErbA. Biochem Biophys Res Commun. 1994;204:49–56. [PubMed]
7. Peña-de-Ortiz S, Jamieson GA., Jr Molecular cloning and brain localization of HZF-2α, a new member of the Rev-erb subfamily of orphan nuclear receptors. J Neurobiol. 1997;32:341–358. [PubMed]
8. Retnakaran R, Flock G, Giguère V. Identification of RVR, a novel orphan nuclear receptor that acts as a negative transcriptional regulator. Mol Endocrinol. 1994;8:1234–1244. [PubMed]
9. Torra IP, et al. Circadian and glucocorticoid regulation of Rev-erbα expression in liver. Endocrinology. 2000;141:3799–3806. [PubMed]
10. Zvonic S, et al. Characterization of peripheral circadian clocks in adipose tissues. Diabetes. 2006;55:962–970. [PubMed]
11. Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 1998;93:929–937. [PubMed]
12. Renaud JP, Harris JM, Downes M, Burke LJ, Muscat GE. Structure-function analysis of the Rev-erbA and RVR ligand-binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains. Mol Endocrinol. 2000;14:700–717. [PubMed]
13. Harding HP, Lazar MA. The monomer-binding orphan receptor Rev-Erb represses transcription as a dimer on a novel direct repeat. Mol Cell Biol. 1995;15:4791–4802. [PMC free article] [PubMed]
14. Burke LJ, Downes M, Laudet V, Muscat GE. Identification and characterization of a novel corepressor interaction region in RVR and Rev-erbAα Mol Endocrinol. 1998;12:248–262. [PubMed]
15. Burke L, Downes M, Carozzi A, Giguère V, Muscat GE. Transcriptional repression by the orphan steroid receptor RVR/Rev-erbβ is dependent on the signature motif and helix 5 in the E region: functional evidence for a biological role of RVR in myogenesis. Nucleic Acids Res. 1996;24:3481–3489. [PMC free article] [PubMed]
16. Guillaumond F, Dardente H, Giguère V, Cermakian N. Differential control of BMAL1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms. 2005;20:391–403. [PubMed]
17. Preitner N, et al. The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–260. [PubMed]
18. Ripperger JA. Mapping of binding regions for the circadian regulators BMAL1 and CLOCK within the mouse Rev-erbα gene. Chronobiol Int. 2006;23:135–142. [PubMed]
19. Hastings MH, et al. Expression of clock gene products in the suprachiasmatic nucleus in relation to circadian behaviour. Novartis Found Symp. 2003;253:203–222. discussion 102–109, 281–284. [PubMed]
20. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4:649–661. [PubMed]
21. Gilles-Gonzalez MA, Gonzalez G. Signal transduction by heme-containing PAS-domain proteins. J Appl Physiol. 2004;96:774–783. [PubMed]
22. Delerive P, Chin WW, Suen CS. Identification of Reverbα as a novel RORα target gene. J Biol Chem. 2002;277:35013–35018. [PubMed]
23. Reinking J, et al. The Drosophila nuclear receptor e75 contains heme and is gas responsive. Cell. 2005;122:195–207. [PubMed]
24. de Rosny E, et al. Drosophila nuclear receptor E75 is a thiolate hemoprotein. Biochemistry. 2006;45:9727–9734. [PubMed]
25. Kaasik K, Lee CC. Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. Nature. 2004;430:467–471. [PubMed]
26. Ben-Shlomo R, et al. Light pulse-induced heme and iron-associated transcripts in mouse brain: a microarray analysis. Chronobiol Int. 2005;22:455–471. [PubMed]
27. Dioum EM, et al. NPAS2: a gas-responsive transcription factor. Science. 2002;298:2385–2387. [PubMed]
28. Ponka P. Cell biology of heme. Am J Med Sci. 1999;318:241–256. [PubMed]
29. Thony-Meyer L. Biogenesis of respiratory cytochromes in bacteria. Microbiol Mol Biol Rev. 1997;61:337–376. [PMC free article] [PubMed]
30. Yu C, et al. Binding analyses between Human PPARγ-LBD and ligands. Eur J Biochem. 2004;271:386–397. [PubMed]
31. Wang L, et al. X-ray crystal structures of the estrogen-related receptor-γ ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J Biol Chem. 2006;281:37773–37781. [PubMed]
32. Ebert PS, Hess RA, Frykholm BC, Tschudy DP. Succinylacetone, a potent inhibitor of heme biosynthesis: effect on cell growth, heme content and δ-aminolevulinic acid dehydratase activity of malignant murine erythroleukemia cells. Biochem Biophys Res Commun. 1979;88:1382–1390. [PubMed]
33. Iwasa F, Sassa S, Kappas A. δ-Aminolaevulinate synthase in human HepG2 hepatoma cells. Repression by haemin and induction by chemicals. Biochem J. 1989;262:807–813. [PubMed]
34. Takahashi S, et al. CYP2E1 overexpression up-regulates both non-specific δ-amino-levulinate synthase and heme oxygenase-1 in the human hepatoma cell line HLE/2E1. Int J Mol Med. 2003;11:57–62. [PubMed]
35. Worthington MT, Cohn SM, Miller SK, Luo RQ, Berg CL. Characterization of a human plasma membrane heme transporter in intestinal and hepatocyte cell lines. Am J Physiol Gastrointest Liver Physiol. 2001;280:G1172–G1177. [PubMed]
36. Wyss PA, Boynton S, Chu J, Roth KS. Tissue distribution of succinylacetone in the rat in vivo: a possible basis for neurotoxicity in hereditary infantile tyrosinemia. Biochim Biophys Acta. 1993;1182:323–328. [PubMed]
37. Tahara T, et al. Heme positively regulates the expression of β-globin at the locus control region via the transcriptional factor Bach1 in erythroid cells. J Biol Chem. 2004;279:5480–5487. [PubMed]
38. Yin L, Lazar MA. The orphan nuclear receptor Rev-erbα recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian BMAL1 gene. Mol Endocrinol. 2005;19:1452–1459. [PubMed]
39. Downes M, Burke LJ, Bailey PJ, Muscat GE. Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbAα and RVR: physical association is dependent on the E region of the orphan receptors. Nucleic Acids Res. 1996;24:4379–4386. [PMC free article] [PubMed]
40. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294:1866–1870. [PubMed]
41. Raspe E, et al. Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription. J Lipid Res. 2002;43:2172–2179. [PubMed]
42. Raspe E, et al. Transcriptional regulation of apolipoprotein C. III gene expression by the orphan nuclear receptor RORα J Biol Chem. 2001;276:2865–2871. [PubMed]
43. Raspe E, et al. Transcriptional regulation of human Rev-erbα gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor α J Biol Chem. 2002;277:49275–49281. [PubMed]
44. Forman BM, et al. Cross-talk among ROR α1 and the Rev-erb family of orphan nuclear receptors. Mol Endocrinol. 1994;8:1253–1261. [PubMed]
45. Coste H, Rodriguez JC. Orphan nuclear hormone receptor Rev-erbα regulates the human apolipoprotein CIII promoter. J Biol Chem. 2002;277:27120–27129. [PubMed]
46. Fontaine C, et al. The orphan nuclear receptor Rev-Erbα is a peroxisome proliferator-activated receptor (PPAR) γ target gene and promotes PPARγ-induced adipocyte differentiation. J Biol Chem. 2003;278:37672–37680. [PubMed]
47. Shimba S, et al. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci USA. 2005;102:12071–12076. [PubMed]
48. Yang X, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell. 2006;126:801–810. [PubMed]
49. Turek FW, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005;308:1043–1045. [PubMed]
50. Rudic RD, et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol. 2004;2:e377. [PMC free article] [PubMed]
51. Handschin C, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1α Cell. 2005;122:505–515. [PubMed]
52. Liu C, Li S, Liu T, Borjigin J, Lin JD. Transcriptional coactivator PGC-1α integrates the mammalian clock and energy metabolism. Nature. 2007;447:477–481. [PubMed]
53. Chen JJ, London IM. Hemin enhances the differentiation of mouse 3T3 cells to adipocytes. Cell. 1981;26:117–122. [PubMed]
54. Myers JK, Pace CN, Scholtz JM. Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Protein Sci. 1995;4:2138–2148. [PubMed]
55. Taille C, et al. Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J Biol Chem. 2004;279:28681–28688. [PubMed]
56. Stayrook KR, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146:984–991. [PubMed]
57. Yin L, Wang J, Klein PS, Lazar MA. Nuclear receptor Rev-erbα is a critical lithium-sensitive component of the circadian clock. Science. 2006;311:1002–1005. [PubMed]
58. Burris TP, et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol. 2005;67:948–954. [PubMed]